📈 Stocks · US

Creative Medical Technology Stock CELZ · Forecast & Analysis

Stocks US
News situation · News, 30 days · no price data
▼ Bearish medium Data coverage thin
Price no dataTrend no price dataNews ▼ 1 report, latest 13.11.

Creative Medical Technology is rated bearish on company news alone: a Nasdaq deficiency notice arrived after CELZ traded below $1.00 for 30 business days, flagging dilution and reverse-split risk. There is no price history to weigh the other side.

News situation · 1 items / 30 D
▼ Bearish medium Data coverage thin
4.0 Impact / 10
By source type
Filing 1

1 of 1 straight from the issuer or regulator

AI-generated · as of November 14, 2026
News, 30 days
Bearish
Outlook

Outlook for Creative Medical Technology Holdings

Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.

What drives it
  • Nasdaq issued a minimum bid price notice on November 10 after 30 straight business days below $1.00.
  • A sub-$1 share price brings dilution and reverse-split risk as the company works to keep its listing.
  • Compliance means closing at $1.00 or higher for ten consecutive business days.
What argues against it
  • The notice has no immediate effect; the Nasdaq listing stands for now.
  • The compliance window runs to May 10, 2027, with a possible second 180-day period if other standards are met.
  • Several high-impact US releases are due in the coming days, a backdrop without a fixed bearing on the stock.
What would change the picture
  • Ten consecutive closes at $1.00 or above would begin to cure the deficiency.
  • Meeting Nasdaq's other initial listing standards would allow a second 180-day grace period.
  • Any reverse-split or dilution step would reshape the path back to compliance.
Coming up
  • US: Retail sales · expected 0.7%, previous 0.9%
  • US: EIA Crude Oil Stocks Change · expected -0.309M, previous 4.657M
  • US: Philadelphia Fed Manufacturing Index, Jobless claims · expected 32.2, previous 20.9
All dates ↓ All times UTC.

Economic data for CELZ

Full calendar

Recently released

  • November 13, 2026USDCore PPI m/m●●●Actual 0.3%Forecast 0.4%Previous 0.8%worse than expected for USD2 days ago
  • November 13, 2026USDPPI m/m●●●Actual 0.3%Forecast 0.4%Previous 1.4%worse than expected for USD2 days ago

Coming up

  • TomorrowUSDCore Retail Sales m/m●●●Forecast 0.7%Previous 0.9%in 1 day
  • TomorrowUSDRetail Sales m/m●●●Forecast 0.3%Previous 0.8%in 1 day
  • November 18, 2026USDEIA Crude Oil Stocks Change●●●Forecast -0.309MPrevious 4.657Min 2 days
  • November 19, 2026USDPhiladelphia Fed Manufacturing Index●●●Forecast 32.2Previous 20.9in 3 days
  • November 19, 2026USDInitial Jobless Claims●●●in 3 days
  • November 20, 2026USDMichigan Consumer Sentiment●●●Forecast 51.0Previous 51.0in 4 days

All times UTC. Assessed against the consensus forecast, otherwise against the previous value.

Signal history

Both worlds over time

Technical and news signals of the last 30 days on one timeline.

Bullish ▲Bearish ▼13.11. · News signal · Impact 4/10
30 days ago today
Technical signal News signal Size = strength
News, 30 days

What is being reported about CELZ

Frequently asked questions about Creative Medical Technology Holdings

What does the Nasdaq notice mean for shareholders right now?

Delisting is not immediate. CELZ has a 180-day grace period, running to May 10, 2027, to bring its closing bid back to $1.00 or higher, and a second 180-day period is possible if the company meets Nasdaq's other initial listing standards. The immediate concern is what the sub-$1 price signals: dilution and reverse-split risk.

How can the deficiency be cured?

The company must close at $1.00 or higher for ten consecutive business days within the grace period ending May 10, 2027. Failing that, a second 180-day window remains available if all other initial listing standards are met. Anything short of that keeps the delisting overhang in place.

How urgent is the risk to the listing itself?

Not urgent in calendar terms, since no listing change happens before the May 2027 deadline and an extension is possible. The urgency sits in the price: the longer the bid stays under a dollar, the likelier dilutive fixes such as a reverse split become. Watch company filings for how management plans to close the gap.

Asset Snapshot

📝 Overview Generated automatically

CELZ has been the subject of 1 signals across 1 articles in the last 365 days. Sentiment skews Bearish (100%).

Breakdown: 0 bullish, 1 bearish, 0 neutral.

Most-cited catalysts: Nasdaq minimum bid price deficiency letter received November 10, 2026 (1×), 180-day compliance deadline of May 10, 2027; must close at $1.00 or higher for ten consecutive business days (1×). Most-cited risk factors: Notice has no immediate impact on the Nasdaq listing (1×), Possible second 180-day grace period if all other initial listing standards are met (1×).